# US 2024/0174611 A1 · Substituted cyclic modulators of protein phosphatase 2a (pp2a) and methods using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0174611 A1
- Document ID: US20240174611A1
- Status: Published application
- Kind: A1
- Application number: 18/273,476
- Filed: 2022-02-07
- Published: 2024-05-30
- Earliest claimed: 2021-02-08
- Assignees: Rappta Therapeutics Oy
- Applicants: Rappta Therapeutics Oy
- Inventors: George L. Trainor; Maria Obdulia Rabal Gracia; Laura Fourmois; Olga Gherbovet; Frederic Cachoux
- Web page: https://patentgrep.com/patent/US20240174611A1

## CPC

- C07D 211/96: Sulfur atom
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C07C 311/29: having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 205/12: condensed with carbocyclic rings or ring systems
- C07D 207/09: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D 207/10: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 207/14: Nitrogen atoms not forming part of a nitro radical
- C07D 207/48: Sulfur atoms
- C07D 209/52: condensed with a ring other than six-membered
- C07D 211/28: to which a second hetero atom is attached
- C07D 211/56: Nitrogen atoms (nitro radicals C07D211/38)
- C07D 211/58: attached in position 4
- C07D 211/76: attached in position 2 or 6
- C07D 231/56: Benzopyrazoles; Hydrogenated benzopyrazoles
- C07D 261/10: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 309/14: Nitrogen atoms not forming part of a nitro radical
- C07D 311/20: hydrogenated in the hetero ring
- C07D 311/68: with nitrogen atoms directly attached in position 4
- C07D 311/96: spiro-condensed with carbocyclic rings or ring systems
- C07D 333/28: Halogen atoms
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 451/04: with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D 487/18: Bridged systems
- C07C 2601/02: with a three-membered ring
- C07C 2601/08: the ring being saturated
- C07C 2601/14: The ring being saturated
- C07C 2601/18: with a ring being at least seven-membered
- C07C 2602/08: the other ring being five-membered, e.g. indane
- C07C 2602/10: the other ring being six-membered, e.g. tetraline
- C07C 2603/74: Adamantanes
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present disclosure relates in part to chemical modulators of protein phosphatase 2A (PP2A). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, autoimmune disease, solid organ transplant rejection, graft vs host disease, chronic obstructive pulmonary disease (COPD), non-alcoholic fatty liver disease, abdominal aortic aneurysm, chronic liver disease, heart failure, neurodegenerative disease, and cardiac hypertrophy.

## Claims

### Claim 1

A compound of formula (Ia), (Ib), (Ic), (Id), (Ie), or (If), or a salt, solvate, enantiomer, diastereoisomer, isotopologue, or tautomer thereof:
wherein:
Ar is C6-C10 aryl or C2-C10 heteroaryl, which is optionally substituted with at least one substituent selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 aminoalkyl, C1-C6 hydroxyalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C10 heteroaryl, C6-C10 aryl, C6-C10 aryloxy, halogen, OH, NH2, CN, NO2, —C(═O)Ra, —C(═O)ORa, and —C(═O)N(Ra)(Ra),
wherein each C6-C10 aryl, C2-C10 heteroaryl, or C6-C10 aryloxy substituent in Ar is independently optionally substituted with at least one substituent selected from the group consisting of C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, F, Cl, Br, I, OH, CN, NO2, —C(═O)ORa, and —C(═O)N(Ra)(Ra), and
wherein two vicinal substituents of Ar may combine to provide a 5- to 8-membered ring which is fused with Ar;
G is optionally substituted C3-C8 cycloalkyl, which is optionally substituted with at least one substituent selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, phenyl, halogen, OH, NH2, CN, NO2, —C(═O)Ra, —C(═O)ORa, and —C(═O)N(Ra)(Ra),
wherein the phenyl in G is optionally substituted with at least one substituent selected from the group consisting of C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, F, Cl, Br, I, OH, CN, NO2, —C(═O)ORa, and —C(═O)N(Ra)(Ra), and
wherein two substituents in G may combine to provide a C3-C8 cycloalkyl which is spiro, fused, or bridged with the C3-C5 cycloalkyl in G;
R1 is selected from the group consisting of
R2 is selected from the group consisting of H, halogen, optionally substituted C1-C6 alkyl, optionally substituted phenyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C2-C10 heterocyclyl, optionally substituted C1-C6 aminoalkyl, optionally substituted C1-C6 alkoxyalkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C2-C6 alkynyl, —C(═O)ORa, and —C(═O)N(Ra)(Ra),
wherein each optional substituent in R2 is at least one selected from the group consisting of halogen, C1-C6 alkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 haloalkyl, —C(═O)ORa, —S(═O)2—C6-C10 aryl, and —S(═O)2—C2-C10 heteroaryl;
R3, R3′, R4, R4′, R5, R5′, R6, R6′, R7, R7′, R8, and R8′ are each independently selected from the group consisting of H, C1-C6 alkyl, hydroxyl, C1-C4 haloalkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C6 heterocyclyl, optionally substituted phenyl, and optionally substituted phenoxy,
wherein each optional substituent in the heterocyclyl, phenyl, or phenoxy is at least one selected from the group consisting of C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, halogen, OH, C(═O)ORa, and C(═O)N(Ra)(Ra),
wherein two geminal substituents selected from R3, R3′, R4, R4′, R5, R5′, R6, R6′, R7, R7′, R8, and R8′ may combine with the carbon atom to which they are bound to form a moiety selected from the group consisting of an optionally substituted C3-C8 cycloalkyl and an optionally substituted C2-C10 heterocyclyl,
wherein two vicinal substituents selected from R3, R3, R4, R4′, R5, R5′, R6, R6′, R7, R7′, R8, and R8′ may combine with the carbon atoms to which they are bound to form a moiety selected from the group consisting of an optionally substituted C3-C5 cycloalkyl, optionally substituted C2-C10 heterocyclyl, and optionally substituted phenyl;
wherein two substituents selected from R3, R3′, R4, R4′, R5, R5′, R6, R6′, R7, R8, and R8′, which are separated by two to five carbon atoms, may combine with the carbon atoms to which they are bound to form a moiety selected from the group consisting of optionally substituted C4-C7 cycloalkyl and optionally substituted C4-C8 heterocyclyl;
R10 is selected from the group consisting of H, C1-C6 alkyl, C3-C6 cycloalkyl, optionally substituted phenyl, optionally substituted benzyl, —C(═O)ORb, —C(═O)Rb, and —S(═O)2-optionally substituted phenyl,
wherein each optional substituent in the phenyl, benzyl, or —S(═O)2-phenyl is independently at least one selected from the group consisting of F, Cl, Br, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 haloalkyl, hydroxyl, and —NH—C(═O)Ra;
R10′ is selected from the group consisting of phenyl, benzyl, and —C(═O)—C1-C6 alkyl, wherein the benzyl or phenyl in R10′ is substituted with at least one substituent selected from the group consisting of halogen, C1-C3 haloalkyl, OH, and N(Ra)(Rb), and wherein the alkyl in R10′ is substituted with at least one phenyl substituent;
Y is selected from the group consisting of C(Ra)(Ra), C═O, NR10, NR10′ and O,
wherein if Y is C(Ra)(Ra) and R2 is optionally substituted phenyl, then Ar comprises a C6-C10 aryl or C2-C10 heteroaryl substituted with at least one trifluoromethoxy substituent;
Z is selected from the group consisting of C═O, NR10, NR10′, O, and S;
RA is H or C1-C6 alkyl;
each occurrence of Ra is independently selected from the group consisting of H, C1-C6 alkyl, benzyl, and C6-C10 aryl; and
each occurrence of Rb is independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, optionally substituted benzyl, optionally substituted phenyl, and optionally substituted naphthyl, wherein the C1-C6 alkyl, benzyl, phenyl, or naphthyl in Rb is independently optionally substituted with at least one selected from the group consisting of C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, halogen, OH, CN, NO2, C(═O)ORa, and C(═O)N(Ra)(Ra);
wherein in (Ia), (Ib), and (Ic), at least one of the following applies:
a) R2 is phenyl or C2-C10 heteroaryl, wherein the phenyl or heteroaryl is optionally substituted with at least one substituent selected from the group consisting of halogen, OH, C1-C3 haloalkoxy, C1-C3 haloalkyl, C1-C3 alkoxy, and C1-C6 alkyl;
b) at least one of R3 and R3′ is phenyl or C2-C10 heteroaryl, wherein the phenyl or heteroaryl is substituted with at least one substituent selected from the group consisting of halogen, OH, C1-C3 haloalkoxy, C1-C3 haloalkyl, C1-C3 alkoxy, and C1-C6 alkyl;
c) at least one of R3, R3′, R4, and R4′, is phenyl or C2-C10 heteroaryl, wherein the phenyl or heteroaryl is optionally substituted with at least one substituent selected from the group consisting of halogen, OH, C1-C3 haloalkoxy, C1-C3 haloalkyl, C1-C3 alkoxy, and C1-C6 alkyl, wherein one of Y and Z is present, and one of Y and Z is selected from the group consisting of C═O, NR10, and O, wherein R10 is selected from the group consisting of H, C3-C6 cycloalkyl, phenyl, optionally substituted benzyl, —C(═O)ORb, —C(═O)Rb, —S(═O)2-optionally substituted phenyl;
d) two geminal substituents selected from R3, R3′, R4, R4′, R5, R5′, R6, R6′, R7, R7′, R8, and R8′ combine with the carbon atom to which they are bound to form a C3-C8 cycloalkyl or C2-C6 heterocyclyl, wherein the cycloalkyl or heterocyclyl is substituted with at least one substituent selected from the group consisting of C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 haloalkoxy, halogen, N(Ra)(Ra), ORa, C(═O)Ra, C(═O)ORa, and C(═O)N(Ra)(Ra),
e) two vicinal substituents selected from R3, R3′, R4, R4′, R5, R5′, R6, R6′, R7, R7′, R8, and R8′ combine with the carbon atoms to which they are bound to form a C3-C5 cycloalkyl, C2-C10 heterocyclyl, or phenyl, wherein the cycloalkyl, heterocyclyl, or phenyl is substituted with at least one substituent selected from the group consisting of C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 haloalkoxy, halogen, ORa, C(═O)Ra, C(═O)ORa, and C(═O)N(Ra)(Ra);
f) two geminal substituents selected from R3, R3′, R4, R4′, R5, R5′, R6, R6′, R7, R7′, R8, and R8′ combine with the carbon atom to which they are bound to form a C3-C8 cycloalkyl or C2-C6 heterocyclyl, and two vicinal substituents selected from R3, R3′, R4, R4′, R5, R5′, R6, R6′, R7, R7′, R8, and R8′ combine with the carbon atoms to which they are bound to form a C3-C5 cycloalkyl, C2-C10 heterocyclyl, or phenyl, wherein each of the cycloalkyl, heterocyclyl, or phenyl is independently optionally substituted with at least one substituent selected from the group consisting of C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 haloalkoxy, halogen, N(Ra)(Ra), ORa, C(═O)Ra, C(═O)ORa, and C(═O)N(Ra)(Ra);
g) Y is N(R10′) and each of R4, R4′, R6, and R6′, if present, are independently selected from the group consisting of H, C1-C6 alkyl, hydroxyl, C1-C4 haloalkyl, phenyl, and phenoxy;
h) at least one of R2, R3, R3′, R4, and R4′ is optionally substituted C3-C8 cycloalkyl or C2-C10 heterocyclyl, wherein each optional substituent in the cycloalkyl or heterocycloalkyl is independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C3 haloalkyl, C1-C3 haloalkoxy, ORa, N(Ra)(Rb), C(═O)Ra, and C(═O)ORa; and
i) R2 is selected from the group consisting of optionally substituted C1-C6 haloalkyl, optionally substituted C2-C6 aminoalkyl and optionally substituted C2-C6 alkynyl, wherein each optional substituent of the haloalkyl, aminoalkyl, and alkynyl in R2 is at least one selected from the group consisting of C1-C6 alkyl, C1-C3 haloalkyl, C1-C3 haloalkoxy, halogen, C(═O)Ra, C(═O)ORa, C(═O)N(Ra)(Ra), S(═O)2-optionally substituted phenyl and S(═O)2-optionally substituted C2-C10 heteroaryl.

### Claim 2 (depends on 1)

The compound of claim 1, which is selected from the group consisting of:
wherein:
each occurrence of R9 is independently selected from the group consisting of F, Cl, Br, C1-C3 alkoxy, and C1-C3 haloalkoxy; and
n is an integer selected from the group consisting of 0, 1, and 2.

### Claim 3 (depends on 1)

The compound of claim 1, wherein RA is selected from the group consisting of H and Me.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R1 is selected from the group consisting of
wherein Ra1 and Ra2 are each independently selected from the group consisting of F, Cl, Br, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, and C1-C3 haloalkoxy.

### Claim 5 (depends on 1)

The compound of claim 1, wherein Ar is selected from the group consisting of
wherein X1, X2, X3, X4, X5, X6, and X7 are each independently selected from the group consisting of C1-C6 alkyl, F, C1, N(Ra)(Rb), ORb, —C(═O)ORa, —C(═O)N(Ra)(Ra), NH2, OH, NO2, C1-C3 haloalkyl, C1-C3 haloalkoxy, and phenyl.

### Claim 6 (depends on 1)

The compound of claim 1, wherein one of the following applies:
(a) the compound is the compound of formula (Ia-1), wherein at least two of R3, R3′, R4, and R4′ are H;
(b) the compound is the compound of formula (Ia-2), wherein at least two of R3, R3′, R4, and R4′ are H;
(c) the compound is the compound of formula (Ia-3), wherein at least four of R3, R3, R4, R4′, R5, and R5 are H;
(d) the compound is the compound of formula (Ia-4), wherein at least one of R3 and R3′ is H;
(e) the compound is the compound of formula (Ia-5), wherein at least two of R3, R3, R4, and R4′ are H;
(f) the compound is the compound of formula (Ia-6), wherein at least six of R3, R3, R4, R4′, R5, R5′, R6, and R6′ are H;
(g) the compound is the compound of formula (Ia-7), wherein at least six of R3, R3, R4, R4′, R5, R5, R6, and R6′ are H;
(h) the compound is the compound of formula (Ia-8), wherein at least ten of R3, R3, R4, R4, R5, R5, R6, R6, R7, R7′, R8, and R8′ are H;
(i) the compound is the compound of formula (Ib-1), wherein at least two of R3, R3, R4, and R4′ are H;
(j) the compound is the compound of formula (Ib-2), wherein at least two of R3, R3′, R4, and R4′ are H;
(k) the compound is the compound of formula (Ib-3), wherein at least four of R3, R3, R4, R4′, R5, and R5 are H;
(1) the compound is the compound of formula (Ib-4), wherein at least one of R3 and R3′ is H;
(m) the compound is the compound of formula (Ib-5), wherein at least two of R3, R3′, R4, and R4′ are H;
(n) the compound is the compound of formula (Ib-6), wherein at least six of R3, R3′, R4, R4′, R5, R5, R6, and R6′ are H;
(o) the compound is the compound of formula (Ib-7), wherein at least six of R3, R3, R4, R4′, R5, R5, R6, and R6′ are H;
(p) the compound is the compound of formula (Ib-8), wherein at least ten of R3, R3′, R4, R4′, R5, R5′, R6, R6′, R7, R7′ R8, and R8′ are H;
(q) the compound is the compound of formula (Ic-1), wherein at least two of R3, R3, R4, and R4′ are H;
(r) the compound is the compound of formula (Ic-2), wherein at least two of R3, R3′, R4, and R4′ are H;
(s) the compound is the compound of formula (Ic-3), wherein at least four of R3, R3, R4, R4′, R5, and R5 are H;
(t) the compound is the compound of formula (Ic-4), wherein at least one of R3 and R3′ is H;
(u) the compound is the compound of formula (Ic-5), wherein at least two of R3, R3, R4, and R4′ are H;
(v) the compound is the compound of formula (Ic-6), wherein at least six of R3, R3, R4, R4′, R5, R5′, R6, and R6′ are H;
(w) the compound is the compound of formula (Ic-7), wherein at least six of R3, R3, R4, R4′, R5, R5′, R6, and R6 are H;
(x) the compound is the compound of formula (Ic-8), wherein at least ten of R3, R3, R4, R4, R5, R1, R6, R1, R7, R7′ R8, and R8′ are H;
(y) the compound is the compound of formula (Id-1), wherein at least six of R3, R3, R4, R4, R, R5, R6, and R6 are H;
(z) the compound is the compound of formula (Ie-1), wherein at least six of R3, R3, R4, R4′, R5, R5′, R6, and R6′ are H; and
(aa) the compound is the compound of formula (If-1), wherein at least six of R3, R3′, R4, R4′, R5, R5′, R6, and R6′ are H.

### Claim 7 (depends on 5)

The compound of claim 5, wherein at least one of X1, X2, X3, X4, X5, X6, and X7 is selected from the group consisting of CF3, NH2, O(CH(CH3)2), OCF3, and

### Claim 8 (depends on 1)

The compound of claim 1, wherein Ar is selected from the group consisting of

### Claim 9 (depends on 1)

The compound of claim 1, wherein G is:
wherein:
R11, R12, R12′, R13, R13′, R14, and R14′ are each independently selected from the group consisting of H, C1-C6 alkyl, C1-C6 haloalkyl, and optionally substituted phenyl,
wherein each optional substituent in the phenyl is at least one selected from the group consisting of C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, halogen, OH, C(═O)ORa, and C(═O)N(Ra)(Ra), and
wherein R11 and R13 or R11 and R13′ may optionally combine with the atoms to which they are bound to form a C3-C5 cycloalkyl.

### Claim 10 (depends on 9)

The compound of claim 9, wherein at least one of the following applies:
(a) at least one of R11, R12, R12′, R13, R13′, R14, and R14′ is H;
(b) at least two of R11, R12, R12′, R13, R13′, R14, and R14′ are H;
(c) at least three of R11, R12, R12′, R13, R13′, R14, and R14′ are H;
(d) at least four of R11, R12, R12′, R13, R13′, R14, and R14′ are H;
(e) at least five of R11, R12, R12′, R13, R13′, R14, and R14′ are H;
(f) at least six of R11, R12, R12′, R13, R13′, R14, and R14′ are H; and
(a) each of R11, R12, R12′, R13, R13′, R14, and R14′ are H.

### Claim 11 (depends on 9)

The compound of claim 9, wherein at least one of R11, R12, R12′, R13, R13′, R14, and R14′ is CF3.

### Claim 12 (depends on 1)

The compound of claim 1, wherein G is

### Claim 13 (depends on 1)

The compound of claim 1, wherein R2 is selected from the group consisting of: —CH2F, —C(═O)OEt, Ph,

### Claim 14 (depends on 1)

The compound of claim 1, wherein at least one of R3, R3′, R4, R4′, R5, R5′, R6, R6′, R7, R7′, R8, and R8′ if-present; is selected from the group consisting of:
methyl, trifluoromethyl, hydroxyl, fluorine, —C(═O)OMe, Ph,

### Claim 15 (depends on 1)

The compound of claim 1, wherein Y is NR10 or NR10′.

### Claim 16 (depends on 15)

The compound of claim 15, wherein one of the following applies:
(a) R10 is selected from the group consisting of H, methyl, 3-methylbutyl, tert-butyl, cyclopropyl, 3-oxetanyl, —C(═O)CH2CH(CH3)2, —C(═O)Ot-Bu, S(═O)2Me, benzyl,
or
(b) R10′ is selected from the group consisting of

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The compound of claim 1, wherein R1 is selected from the group consisting of

### Claim 20

A compound of formula (IIa), (IIb, or (IIc), or a salt, solvate, enantiomer, diastereoisomer, isotopologue, or tautomer thereof:
wherein:
Ar is C6-C10 aryl or C2-C10 heteroaryl, which is optionally substituted with at least one substituent selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 aminoalkyl, C1-C6 hydroxyalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C10 heteroaryl, C6-C10 aryl, C6-C10 aryloxy, halogen, OH, NH2, CN, NO2, —C(═O)ORa, and —C(═O)N(Ra)(Ra),
wherein each C6-C10 aryl, C2-C10 heteroaryl, or C6-C10 aryloxy substituent in Ar is independently optionally substituted with at least one substituent selected from the group consisting of C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, F, Cl, Br, I, OH, CN, NO2, —C(═O)ORa, and —C(═O)N(Ra)(Ra), and
wherein two vicinal substituents of Ar may combine to provide a 5- to 8-membered ring which is fused with Ar;
each occurrence of Ra is independently selected from the group consisting of H, C1-C6 alkyl, benzyl, and C6-C10 aryl;
RA is H or C1-C6 alkyl; and
R1 is selected from the group consisting of

### Claim 21 (depends on 20)

The compound of claim 20, wherein RA is H or Me.

### Claim 22 (depends on 20)

The compound of claim 20, wherein Ar is selected from the group consisting of
wherein X1, X2, X3, X4, X5, X6, and X7 are each independently selected from the group consisting of C1-C6 alkyl, F, Cl, N(Ra)(Rb), ORb, —C(═O)ORa, —C(═O)N(Ra)(Ra), NH2, OH, NO2, C1-C3 haloalkyl, C1-C3 haloalkoxy, and phenyl.

### Claim 23 (depends on 20)

The compound of claim 20, wherein at least one of X1, X2, X3, X4, X5, X6, and X7 is selected from the group consisting of CF3, CF3, NH2, O(CH(CH3)2), OCF3, and

### Claim 24 (depends on 20)

The compound of claim 20, wherein Ar is selected from the group consisting of

### Claim 25 (depends on 1)

The compound of claim 1, which is selected from the group consisting of:
N-(6-fluoro-2,2-dimethylchroman-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(1-(tert-butyl)-2-(4-chloro-3-fluorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
tert-butyl 4-(2-((4-(trifluoromethoxy)phenyl)sulfonamido)cyclopropyl)piperidine-1-carboxylate;
tert-butyl 2-(1-((4-(trifluoromethoxy)phenyl)sulfonamido)cyclopropyl)pyrrolidine-1-carboxylate;
N-(6-(difluoromethoxy)-4-oxo-1,2,3,4-tetrahydronaphthalen-1-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(1-(3-ethoxy-4-hydroxybenzyl)piperidin-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
tert-butyl 3-(fluoromethyl)-3-((4-(trifluoromethoxy)phenyl)sulfonamido)pyrrolidine-1-carboxylate;
N-(1-cyclopropyl-2-(3,4-difluorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(2-oxo-1-(3-(trifluoromethyl)benzyl)piperidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(spiro[chromane-2,1′-cyclopentan]-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(1-benzyl-3-phenylpyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(4-(3-fluoro-4-methoxyphenyl)tetrahydro-2H-pyran-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(3-phenylpyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(1-(3-chlorophenyl)cyclopentyl)-4-(trifluoromethoxy)benzenesulfonamide;
methyl 3-(1-((4-(trifluoromethoxy)phenyl)sulfonamido)cyclopentyl)propiolate;
N-(4,6-dichloro-2,3-dihydro-1H-inden-1-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-2-benzyl-7-hydroxy-1-isopropyl-2-azaspiro[3.4]octan-6-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(6-chloro-1,2,3,4-tetrahydronaphthalen-1-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(1-(3-methoxyphenyl)cyclopentyl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(2-(4-chlorophenyl)-1-methylpyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(1-(3,4-dichlorophenyl)piperidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
3,5-dimethyl-N-((1-((4-(trifluoromethoxy)phenyl)sulfonamido)cyclohexyl)methyl)isoxazole-4-sulfonamide;
N-(1-(2-phenylbutanoyl)piperidin-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
4-(trifluoromethoxy)-N-(1-(3-(trifluoromethoxy)phenyl)pyrrolidin-3-yl)benzenesulfonamide;
N-(2-ethyl-1-(m-tolyl)cyclopropyl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(1-(5-chloro-2-methoxyphenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(5,8-difluorochroman-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(2-(4-chlorophenyl)cyclopropyl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(2-(3,4-dichlorophenyl)cyclopentyl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(3-(4-chlorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(3-(3,4-dichlorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(4-(4-chlorophenyl)piperidin-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(1-(3-bromophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(3-(4-chlorophenyl)azetidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(3-(3,4-dichlorophenyl)azetidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(4-(3,4-dichlorophenyl)piperidin-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(4-phenylpiperidin-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
benzyl 3-(3,4-dichlorophenyl)-3-((4-(trifluoromethoxy)phenyl)sulfonamido)pyrrolidine-1-carboxylate;
N-(3-(4-chloro-3-fluorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
tert-butyl 4-(4-chlorophenyl)-4-((4-(trifluoromethoxy)phenyl)sulfonamido)piperidine-1-carboxylate;
N-(1-benzyl-3-(4-chlorophenyl)pyrrolidin-3-yl)-4-(4-(trifluoromethyl)phenoxy)benzenesulfonamide;
N-(1-benzyl-3-(3,4-dichlorophenyl)pyrrolidin-3-yl)-4-(4-(trifluoromethyl)phenoxy)benzenesulfonamide;
N-(4-(4-chloro-3-fluorophenyl)piperidin-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(3-(4-chlorophenyl)pyrrolidin-3-yl)-4-(4-(trifluoromethyl)phenoxy)benzenesulfonamide;
N-(3-(4-chloro-3-fluorophenyl)azetidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(4-(4-fluorophenyl)piperidin-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(4-phenylpiperidin-4-yl)-6-(trifluoromethoxy)pyridine-3-sulfonamide;
N-(1-methyl-4-phenylpiperidin-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(4-(4-chlorophenyl)piperidin-4-yl)-4-isopropoxybenzenesulfonamide;
N-(3-(4-chlorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonimidamide;
N-(3-(4-chlorophenyl)pyrrolidin-3-yl)-6-(trifluoromethoxy)pyridine-3-sulfonamide;
N-(4-(5-fluoropyridin-2-yl)piperidin-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(4-(bicyclo[1.1.1]pentan-1-yl)piperidin-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(4-(4-chlorophenyl)piperidin-4-yl)-6-isopropoxypyridine-3-sulfonamide;
N-(3-(4-chlorophenyl)pyrrolidin-3-yl)-N′-methyl-4-(trifluoromethoxy)benzenesulfonimidamide;
N-(3-(4-chlorophenyl)-1-methylpyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
tert-butyl 3-(4-chlorophenyl)-3-((4-(trifluoromethoxy)phenyl)sulfonamido)pyrrolidine-1-carboxylate;
N-(3-(4-chlorophenyl)-1-(oxetan-3-yl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(3-(4-chlorophenyl)-1-(methylsulfonyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(4-(5-chlorothiazol-2-yl)piperidin-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(3-(4-fluorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(4-(4-fluorophenyl)piperidin-4-yl)-4-isopropoxybenzenesulfonamide;
N-(3-(4-chlorophenyl)-1-isopentylpyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(4-(4-fluorophenyl)piperidin-4-yl)-6-isopropoxypyridine-3-sulfonamide;
N-(3-(4-fluorophenyl)pyrrolidin-3-yl)-4-isopropoxybenzenesulfonamide;
rac N-((3S,4S)-3-(4-chlorophenyl)-4-fluoropyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(3-(4-chlorophenyl)pyrrolidin-3-yl)-6-isopropoxypyridine-3-sulfonamide;
N-(3-(4-chlorophenyl)-1-(3-methylbutanoyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(4-(3,4-difluorophenyl)piperidin-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(4-(2,4-difluorophenyl)piperidin-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(3-(4-fluorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonimidamide;
N-(3-(4-chlorophenyl)pyrrolidin-3-yl)-N-methyl-4-(trifluoromethoxy)benzenesulfonamide;
N-(3-phenyl-8-azabicyclo[3.2.1]octan-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(4-(5-chloropyridin-2-yl)piperidin-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(4-(2,5-difluorophenyl)piperidin-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(1-(3,4-dichlorophenyl)cyclopropyl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(3-phenylpiperidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(4-(5-chlorothiophen-2-yl)piperidin-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
3-amino-N-(3-(4-fluorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
3-amino-N-(3-(4-fluoro-3-methylphenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(4-(4-chloro-2-fluorophenyl)piperidin-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-(4-(5-chloro-3-fluoropyridin-2-yl)piperidin-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N′-(4-(4-chlorophenyl)piperidin-4-yl)-4-(trifluoromethoxy)benzenesulfonimidamide;
N-(4-(4-chlorophenyl)piperidin-4-yl)-4-(trifluoromethyl)benzenesulfonamide;
N-(4-(4-chlorophenyl)piperidin-4-yl)-3-(trifluoromethyl)bicyclo[1.1.1]pentane-1-sulfonamide;
3-amino-N-(4-(4-chlorophenyl)piperidin-4-yl)-4-(trifluoromethoxy)benzenesulfonamide; and
N-(4-(4-(difluoromethyl)phenyl)piperidin-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
or a salt, solvate, isotopologue, or tautomer thereof.

### Claim 26 (depends on 1)

The compound of claim 1, which is selected from the group consisting of:
(R)—N-(6-fluoro-2,2-dimethylchroman-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((2R,3R)-1-(tert-butyl)-2-(4-chloro-3-fluorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((2R,3S)-1-(tert-butyl)-2-(4-chloro-3-fluorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
tert-butyl 4-((1R,2R)-2-((4-(trifluoromethoxy)phenyl)sulfonamido)cyclopropyl)piperidine-1-carboxylate;
tert-butyl 4-((1R,2S)-2-((4-(trifluoromethoxy)phenyl)sulfonamido)cyclopropyl)piperidine-1-carboxylate;
(R)-tert-butyl 2-(1-((4-(trifluoromethoxy)phenyl)sulfonamido)cyclopropyl)pyrrolidine-1-carboxylate;
(R)—N-(6-(difluoromethoxy)-4-oxo-1,2,3,4-tetrahydronaphthalen-1-yl)-4-(trifluoromethoxy)benzenesulfonamide;
tert-butyl (R)-3-(fluoromethyl)-3-((4-(trifluoromethoxy)phenyl)sulfonamido)pyrrolidine-1-carboxylate;
N-((2R,3R)-1-cyclopropyl-2-(3,4-difluorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((2R,3S)-1-cyclopropyl-2-(3,4-difluorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)—N-(2-oxo-1-(3-(trifluoromethyl)benzyl)piperidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)—N-(spiro[chromane-2,1′-cyclopentan]-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)—N-(1-benzyl-3-phenylpyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)—N-(3-phenylpyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)—N-(4,6-dichloro-2,3-dihydro-1H-inden-1-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((6R,7R)-2-benzyl-7-hydroxy-1-isopropyl-2-azaspiro[3.4]octan-6-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((6R,7S)-2-benzyl-7-hydroxy-1-isopropyl-2-azaspiro[3.4]octan-6-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)—N-(6-chloro-1,2,3,4-tetrahydronaphthalen-1-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((2R,3R)-2-(4-chlorophenyl)-1-methylpyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((2R,3S)-2-(4-chlorophenyl)-1-methylpyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)—N-(1-(3,4-dichlorophenyl)piperidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)—N-(1-(2-phenylbutanoyl)piperidin-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)-4-(trifluoromethoxy)-N-(1-(3-(trifluoromethoxy)phenyl)pyrrolidin-3-yl)benzenesulfonamide;
N-((1R,2R)-2-ethyl-1-(m-tolyl)cyclopropyl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((1R,2S)-2-ethyl-1-(m-tolyl)cyclopropyl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)—N-(1-(5-chloro-2-methoxyphenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)—N-(5,8-difluorochroman-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((1R,2R)-2-(4-chlorophenyl)cyclopropyl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((1R,2S)-2-(4-chlorophenyl)cyclopropyl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((1R,2R)-2-(3,4-dichlorophenyl)cyclopentyl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((1R,2S)-2-(3,4-dichlorophenyl)cyclopentyl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)—N-(3-(4-chlorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)—N-(3-(3,4-dichlorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)—N-(1-(3-bromophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)-benzyl 3-(3,4-dichlorophenyl)-3-((4-(trifluoromethoxy)phenyl)sulfonamido)pyrrolidine-1-carboxylate;
N-((3R,4R)-4-(3,4-dichlorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((3R,4S)-4-(3,4-dichlorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)—N-(3-(4-chloro-3-fluorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)—N-(1-benzyl-3-(4-chlorophenyl)pyrrolidin-3-yl)-4-(4-(trifluoromethyl)phenoxy)benzenesulfonamide;
(R)—N-(1-benzyl-3-(3,4-dichlorophenyl)pyrrolidin-3-yl)-4-(4-(trifluoromethyl)phenoxy)benzenesulfonamide;
(R)—N-(3-(4-chlorophenyl)pyrrolidin-3-yl)-4-(4-(trifluoromethyl)phenoxy)benzenesulfonamide;
(R)—N—((R)-3-(4-chlorophenyl)yrrolidine-3-yl)-4-(trifluoromethoxy)benzenesulfonimidamide;
(R)—N—((S)-3-(4-chlorophenyl)yrrolidine-3-yl)-4-(trifluoromethoxy)benzenesulfonimidamide;
(R)—N-(3-(4-chlorophenyl)yrrolidine-3-yl)-6-(trifluoromethoxy)pyridine-3-sulfonamide;
(R)—N—((R)-3-(4-chlorophenyl)yrrolidine-3-yl)-N′-methyl-4-(trifluoromethoxy)benzenesulfonimidamide;
(R)—N—((S)-3-(4-chlorophenyl)yrrolidine-3-yl)-N′-methyl-4-(trifluoromethoxy)benzenesulfonimidamide;
(R)—N-(3-(4-chlorophenyl)-1-methylpyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
tert-butyl (R)-3-(4-chlorophenyl)-3-((4-(trifluoromethoxy)phenyl)yrrolidine)pyrrolidine-1-carboxylate;
(R)—N-(3-(4-chlorophenyl)-1-(oxetan-3-yl)yrrolidine-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)—N-(3-(4-chlorophenyl)-1-(methylsulfonyl)yrrolidine-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)—N-(3-(4-fluorophenyl)yrrolidine-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)—N-(3-(4-chlorophenyl)-1-isopentylpyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)—N-(3-(4-fluorophenyl)yrrolidine-3-yl)-4-isopropoxybenzenesulfonamide;
N-((3R,4R)-3-(4-chlorophenyl)-4-fluoropyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((3R,4S)-3-(4-chlorophenyl)-4-fluoropyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)—N-(3-(4-chlorophenyl)yrrolidine-3-yl)-6-isopropoxypyridine-3-sulfonamide;
(R)—N-(3-(4-chlorophenyl)-1-(3-methylbutanoyl)yrrolidine-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)—N—((R)-3-(4-fluorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonimidamide;
(R)—N—((S)-3-(4-fluorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonimidamide;
(R)—N-(3-(4-chlorophenyl)pyrrolidin-3-yl)-N-methyl-4-(trifluoromethoxy)benzenesulfonamide;
(R)—N-(3-phenylpiperidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)-3-amino-N-(3-(4-fluorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide; and
(R)-3-amino-N-(3-(4-fluoro-3-methylphenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)—N-(6-fluoro-2,2-dimethylchroman-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((2S,3S)-1-(tert-butvl)-2-(4-chloro-3-fluorophenvl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((2S,3R)-1-(tert-butyl)-2-(4-chloro-3-fluorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
tert-butyl 4-((1S,2S)-2-((4-(trifluoromethoxy)phenvl)sulfonamido)cyclopropyl)piperidine-1-carboxylate;
tert-butyl 4-((1S,2R)-2-((4-(trifluoromethoxy)phenyl)sulfonamido)cyclopropyl)piperidine-1-carboxylate;
(S)-tert-butyl 2-(1-((4-(trifluoromethoxy)phenyl)sulfonamido)cyclopropyl)pyrrolidine-1-carboxylate;
(S)—N-(6-(difluoromethoxy)-4-oxo-1,2,3,4-tetrahydronaphthalen-1-yl)-4-(trifluoromethoxy)benzenesulfonamide;
tert-butyl (S)-3-(fluoromethyl)-3-((4-(trifluoromethoxy)phenyl)sulfonamido)pyrrolidine-1-carboxylate;
N-((2S,3S)-1-cyclopropyl-2-(3,4-difluorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((2S,3R)-1-cyclopropyl-2-(3,4-difluorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)—N-(2-oxo-1-(3-(trifluoromethyl)benzyl)piperidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)—N-(spiro[chromane-2,1′-cyclopentan]-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)—N-(1-benzyl-3-phenylpyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)—N-(3-phenylpyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)—N-(4,6-dichloro-2,3-dihydro-1H-inden-1-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((6S,7S)-2-benzyl-7-hydroxy-1-isopropyl-2-azaspiro[3.4]octan-6-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((6S,7R)-2-benzyl-7-hydroxy-1-isopropyl-2-azaspiro[3.4]octan-6-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)—N-(6-chloro-1,2,3,4-tetrahydronaphthalen-1-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((2S,3S)-2-(4-chlorophenyl)-1-methylpyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((2S,3R)-2-(4-chlorophenyl)-1-methylpyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)—N-(1-(3,4-dichlorophenyl)piperidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)—N-(1-(2-phenylbutanoyl)piperidin-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)-4-(trifluoromethoxy)-N-(1-(3-(trifluoromethoxy)phenyl)pyrrolidin-3-yl)benzenesulfonamide;
N-((1S,2S)-2-ethyl-1-(m-tolyl)cyclopropyl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((1S,2R)-2-ethyl-1-(m-tolyl)cyclopropyl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)—N-(1-(5-chloro-2-methoxyphenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)—N-(5,8-difluorochroman-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((1S,2S)-2-(4-chlorophenyl)cyclopropyl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((1S,2R)-2-(4-chlorophenyl)cyclopropyl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((1S,2S)-2-(3,4-dichlorophenyl)cyclopentyl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((1R,2S)-2-(3,4-dichlorophenyl)cyclopentyl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)—N-(3-(4-chlorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)—N-(3-(3,4-dichlorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)—N-(1-(3-bromophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)-benzyl 3-(3,4-dichlorophenyl)-3-((4-(trifluoromethoxy)phenyl)sulfonamido)pyrrolidine-1-carboxylate;
N-((3S,4S)-4-(3,4-dichlorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((3S,4R)-4-(3,4-dichlorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)—N-(3-(4-chloro-3-fluorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)—N-(1-benzyl-3-(4-chlorophenyl)pyrrolidin-3-yl)-4-(4-(trifluoromethyl)phenoxy)benzenesulfonamide;
(S)—N-(1-benzyl-3-(3,4-dichlorophenyl)pyrrolidin-3-yl)-4-(4-(trifluoromethyl)phenoxy)benzenesulfonamide;
(S)—N-(3-(4-chlorophenyl)pyrrolidin-3-yl)-4-(4-(trifluoromethyl)phenoxy)benzenesulfonamide;
(S)—N—((S)-3-(4-chlorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonimidamide;
(S)—N—((R)-3-(4-chlorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonimidamide;
(S)—N-(3-(4-chlorophenyl)pyrrolidin-3-yl)-6-(trifluoromethoxy)pyridine-3-sulfonamide;
(S)—N—((S)-3-(4-chlorophenyl)pyrrolidin-3-yl)-N′-methyl-4-(trifluoromethoxy)benzenesulfonimidamide;
(S)—N—((R)-3-(4-chlorophenyl)pyrrolidin-3-yl)-N′-methyl-4-(trifluoromethoxy)benzenesulfonimidamide;
(S)—N-(3-(4-chlorophenyl)-1-methylpyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
tert-butyl (S)-3-(4-chlorophenyl)-3-((4-(trifluoromethoxy)phenyl)sulfonamido)pyrrolidine-1-carboxylate;
(S)—N-(3-(4-chlorophenyl)-1-(oxetan-3-yl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)—N-(3-(4-chlorophenyl)-1-(methylsulfonyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)—N-(3-(4-fluorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)—N-(3-(4-chlorophenyl)-1-isopentylpyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)—N-(3-(4-fluorophenyl)pyrrolidin-3-yl)-4-isopropoxybenzenesulfonamide;
N-((3S,4S)-3-(4-chlorophenyl)-4-fluoropyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((3S,4R)-3-(4-chlorophenyl)-4-fluoropyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)—N-(3-(4-chlorophenyl)pyrrolidin-3-yl)-6-isopropoxypyridine-3-sulfonamide;
(S)—N-(3-(4-chlorophenyl)-1-(3-methylbutanoyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)—N—((S)-3-(4-fluorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonimidamide;
(S)—N—((R)-3-(4-fluorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonimidamide;
(S)—N-(3-(4-chlorophenyl)pyrrolidin-3-yl)-N-methyl-4-(trifluoromethoxy)benzenesulfonamide;
(S)—N-(3-phenylpiperidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)-3-amino-N-(3-(4-fluorophenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide; and
(S)-3-amino-N-(3-(4-fluoro-3-methylphenyl)pyrrolidin-3-yl)-4-(trifluoromethoxy)benzenesulfonamide;
or a salt, solvate, isotopologue, or tautomer thereof.

### Claim 27

(canceled)

### Claim 28

A compound selected from the group consisting of:
N-(4-((4-((4-(trifluoromethoxy)phenyl)sulfonamido)piperidin-1-yl)sulfonyl)phenyl)acetamide;
methyl 1-((4-(trifluoromethoxy)phenyl)sulfonamido)-2,3-dihydro-1H-indene-2-carboxylate;
methyl (1R,2R)-1-((4-(trifluoromethoxy)phenyl)sulfonamido)-2,3-dihydro-1H-indene-2-carboxylate;
methyl (1R,2S)-1-((4-(trifluoromethoxy)phenyl)sulfonamido)-2,3-dihydro-1H-indene-2-carboxylate;
methyl (1S,2S)-1-((4-(trifluoromethoxy)phenyl)sulfonamido)-2,3-dihydro-1H-indene-2-carboxylate;
methyl (1S,2R)-1-((4-(trifluoromethoxy)phenyl)sulfonamido)-2,3-dihydro-1H-indene-2-carboxylate;
N-(2-(4-fluorophenoxy)cyclohexyl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((1R,2R)-2-(4-fluorophenoxy)cyclohexyl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((1R,2S)-2-(4-fluorophenoxy)cyclohexyl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((1S,2S)-2-(4-fluorophenoxy)cyclohexyl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((1S,2R)-2-(4-fluorophenoxy)cyclohexyl)-4-(trifluoromethoxy)benzenesulfonamide;
4-(trifluoromethoxy)-N-(3,4,4-trimethylcyclohexyl)benzenesulfonamide;
(R)-4-(trifluoromethoxy)-N-(3,4,4-trimethylcyclohexyl)benzenesulfonamide;
(S)-4-(trifluoromethoxy)-N-(3,4,4-trimethylcyclohexyl)benzenesulfonamide;
4-(trifluoromethoxy)-N-((1R,3R)-3,4,4-trimethylcyclohexyl)benzenesulfonamide;
4-(trifluoromethoxy)-N-((1R,3S)-3,4,4-trimethylcyclohexyl)benzenesulfonamide;
4-(trifluoromethoxy)-N-((1S,3S)-3,4,4-trimethylcyclohexyl)benzenesulfonamide;
4-(trifluoromethoxy)-N-((1S,3R)-3,4,4-trimethylcyclohexyl)benzenesulfonamide;
N-(2-phenylcycloheptyl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((1R,2R)-2-phenylcycloheptyl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((1R,2S)-2-phenylcycloheptyl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((1S,2S)-2-phenylcycloheptyl)-4-(trifluoromethoxy)benzenesulfonamide;
N-((1S,2R)-2-phenylcycloheptyl)-4-(trifluoromethoxy)benzenesulfonamide;
ethyl 1-((4-(trifluoromethoxy)phenyl)sulfonamido)-2,3-dihydro-1H-indene-1-carboxylate;
ethyl (R)-1-((4-(trifluoromethoxy)phenyl)sulfonamido)-2,3-dihydro-1H-indene-1-carboxylate;
ethyl (S)-1-((4-(trifluoromethoxy)phenyl)sulfonamido)-2,3-dihydro-1H-indene-1-carboxylate;
methyl 3,5-dimethyl-7-((4-(trifluoromethoxy)phenyl)sulfonamido)adamantane-1-carboxylate;
N-(2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(R)—N-(2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
(S)—N-(2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-(trifluoromethoxy)benzenesulfonamide;
4-(trifluoromethoxy)-N-(4-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-6-yl)benzenesulfonamide;
4-(trifluoromethoxy)-N-((4R,6R)-4-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-6-yl)benzenesulfonamide;
4-(trifluoromethoxy)-N-((4R,6S)-4-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-6-yl)benzenesulfonamide;
4-(trifluoromethoxy)-N-((4S,6S)-4-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-6-yl)benzenesulfonamide; and
4-(trifluoromethoxy)-N-((4S,6R)-4-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-6-yl)benzenesulfonamide;
or a salt, solvate, isotopologue, or tautomer thereof.

### Claim 29 (depends on 1)

A pharmaceutical composition comprising at least one compound of claim 1 and at least one pharmaceutically acceptable carrier.

### Claim 30 (depends on 1)

A method of treating, preventing, or ameliorating a PP2A-related disease in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of the compound of claim 1 or a pharmaceutical composition thereof comprising at least one pharmaceutically acceptable carrier.

### Claim 31 (depends on 30)

The method of claim 30, wherein the PP2A-related disease is at least one selected from the group consisting of cancer, diabetes, autoimmune disease, solid organ transplant rejection, graft vs host disease, chronic obstructive pulmonary disease (COPD), non-alcoholic fatty liver disease, abdominal aortic aneurysm, chronic liver disease, heart failure, neurodegenerative disease, and cardiac hypertrophy.

### Claim 32 (depends on 30)

The method of claim 30, wherein the subject is a mammal, optionally wherein the mammal is a human.

### Claim 33

(canceled)
